|
1
|
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.
|
Cancer Cell
|
2009
|
8.21
|
|
2
|
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
|
Clin Cancer Res
|
2005
|
5.16
|
|
3
|
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.
|
Nat Med
|
2005
|
3.01
|
|
4
|
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.
|
Sci Transl Med
|
2011
|
2.04
|
|
5
|
Side population keratinocytes resembling bone marrow side population stem cells are distinct from label-retaining keratinocyte stem cells.
|
J Invest Dermatol
|
2003
|
1.83
|
|
6
|
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
|
J Hepatol
|
2013
|
1.80
|
|
7
|
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
|
J Immunol
|
2007
|
1.57
|
|
8
|
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
|
Clin Cancer Res
|
2011
|
1.53
|
|
9
|
Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.
|
Am J Respir Cell Mol Biol
|
2010
|
1.51
|
|
10
|
CCL2 blockade augments cancer immunotherapy.
|
Cancer Res
|
2009
|
1.48
|
|
11
|
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
|
Clin Cancer Res
|
2007
|
1.47
|
|
12
|
Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils.
|
PLoS One
|
2012
|
1.40
|
|
13
|
Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
|
Cancer Res
|
2005
|
1.40
|
|
14
|
Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine.
|
Clin Cancer Res
|
2006
|
1.40
|
|
15
|
Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery.
|
Proc Natl Acad Sci U S A
|
2012
|
1.40
|
|
16
|
Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.
|
Cancer Res
|
2008
|
1.38
|
|
17
|
Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1.
|
PLoS Biol
|
2010
|
1.35
|
|
18
|
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.
|
Clin Cancer Res
|
2008
|
1.32
|
|
19
|
Intraoperative near-infrared imaging of surgical wounds after tumor resections can detect residual disease.
|
Clin Cancer Res
|
2012
|
1.30
|
|
20
|
Rho exchange factor ECT2 is induced by growth factors and regulates cytokinesis through the N-terminal cell cycle regulator-related domains.
|
J Cell Biochem
|
2003
|
1.29
|
|
21
|
Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung.
|
Cancer Res
|
2005
|
1.26
|
|
22
|
Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.
|
Mol Ther
|
2010
|
1.23
|
|
23
|
Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion.
|
Blood
|
2008
|
1.20
|
|
24
|
Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects.
|
Cancer Biol Ther
|
2007
|
1.15
|
|
25
|
The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer.
|
Mol Cancer Ther
|
2009
|
1.15
|
|
26
|
Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
|
Hum Gene Ther
|
2010
|
1.14
|
|
27
|
CCL25 increases thymopoiesis after androgen withdrawal.
|
Blood
|
2008
|
1.11
|
|
28
|
Stem cell activity of human side population and alpha6 integrin-bright keratinocytes defined by a quantitative in vivo assay.
|
Stem Cells
|
2006
|
1.11
|
|
29
|
Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
|
Cancer Immunol Res
|
2013
|
1.07
|
|
30
|
B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
|
J Immunother
|
2008
|
1.07
|
|
31
|
The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes.
|
Cancer Res
|
2007
|
1.06
|
|
32
|
Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.
|
Mol Ther
|
2011
|
1.06
|
|
33
|
Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma.
|
J Thorac Cardiovasc Surg
|
2004
|
1.05
|
|
34
|
Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
|
Cancer Res
|
2003
|
1.04
|
|
35
|
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
|
Clin Cancer Res
|
2004
|
1.02
|
|
36
|
Inhibition of p300 impairs Foxp3⁺ T regulatory cell function and promotes antitumor immunity.
|
Nat Med
|
2013
|
1.02
|
|
37
|
Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution.
|
Blood
|
2004
|
1.01
|
|
38
|
A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.
|
Cancer Biol Ther
|
2012
|
1.00
|
|
39
|
Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
|
Cancer Gene Ther
|
2003
|
1.00
|
|
40
|
Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery.
|
Neoplasia
|
2012
|
0.96
|
|
41
|
Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway.
|
Blood
|
2008
|
0.95
|
|
42
|
Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness.
|
J Hematol Oncol
|
2012
|
0.94
|
|
43
|
Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
|
Eur J Cancer
|
2010
|
0.94
|
|
44
|
Behavior of human foreskin keratinocytes expressing a hair follicle stem cell marker CD200.
|
J Invest Dermatol
|
2007
|
0.93
|
|
45
|
New lasers for flow cytometry: filling the gaps.
|
Nat Methods
|
2007
|
0.91
|
|
46
|
Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.
|
Biochem Pharmacol
|
2011
|
0.91
|
|
47
|
Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery.
|
Ann Surg
|
2005
|
0.88
|
|
48
|
IFN-γ regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1.
|
Eur J Immunol
|
2014
|
0.86
|
|
49
|
Pharmacologic activation of the innate immune system to prevent respiratory viral infections.
|
Am J Respir Cell Mol Biol
|
2010
|
0.85
|
|
50
|
Characterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessment.
|
Am J Transl Res
|
2012
|
0.83
|
|
51
|
Adenoviral-based immunotherapy provides local disease control in an orthotopic murine model of esophageal cancer.
|
J Immunother
|
2014
|
0.81
|
|
52
|
Tbata modulates thymic stromal cell proliferation and thymus function.
|
J Exp Med
|
2010
|
0.80
|
|
53
|
Blockade of TNF-alpha decreases both inflammation and efficacy of intrapulmonary Ad.IFNbeta immunotherapy in an orthotopic model of bronchogenic lung cancer.
|
Mol Ther
|
2006
|
0.80
|
|
54
|
High levels of IL-7 cause dysregulation of thymocyte development.
|
Int Immunol
|
2012
|
0.80
|
|
55
|
Sensitive GC-MS/MS method to measure deuterium labeled deoxyadenosine in DNA from limited mouse cell populations.
|
Anal Chem
|
2013
|
0.77
|
|
56
|
Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner.
|
Eur J Immunol
|
2015
|
0.77
|
|
57
|
Violet laser diodes in flow cytometry: an update.
|
Cytometry A
|
2006
|
0.77
|
|
58
|
The minimal instrumentation requirements for Hoechst side population analysis: stem cell analysis on low-cost flow cytometry platforms.
|
Stem Cells
|
2006
|
0.76
|
|
59
|
Clustered carbohydrates as a target for natural killer cells: a model system.
|
Histochem Cell Biol
|
2007
|
0.75
|
|
60
|
Genetic immunization with LYVE-1 cDNA yields function-blocking antibodies against native protein.
|
Microvasc Res
|
2005
|
0.75
|
|
61
|
Stent-mediated gene delivery for site-specific transgene administration to the airway epithelium and management of tracheobronchial tumors.
|
Respiration
|
2014
|
0.75
|